Multiple primary melanomas: Our experience

Ungureanu,Loredana; Zboraș,Iulia; Vasilovici,Alina; Vesa,Ștefan; Cosgarea,Ioana; Cosgarea,Rodica; Șenilă,Simona

doi:10.3892/etm.2020.9520

Multiple primary melanomas: Our experience

Authors:
- Loredana Ungureanu
- Iulia Zboraș
- Alina Vasilovici
- Ștefan Vesa
- Ioana Cosgarea
- Rodica Cosgarea
- Simona Șenilă
View Affiliations

Affiliations: Department of Dermatology, ‘Iuliu Hațieganu’ University of Medicine and Pharmacy, 400006 Cluj‑Napoca, Romania, Department of Pharmacology, ‘Iuliu Hațieganu’ University of Medicine and Pharmacy, Toxicology and Clinical Pharmacology, 400012 Cluj‑Napoca, Romania, Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
Published online on: November 26, 2020 https://doi.org/10.3892/etm.2020.9520
Article Number: 88
Copyright: © Ungureanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with melanoma have an increased risk of having other neoplasms, and particularly other melanomas and non‑melanoma skin cancers. The study aimed to describe multiple primary melanomas in a large medical university centre from Romania (Cluj‑Napoca) from 2004 to 2020. Out of 699 patients with melanoma included in the study, 26 (3.71%) developed multiple tumours. The 26 patients developed a total of 59 melanomas, corresponding to a mean of 2.3 melanomas per patient. The site and histological subtype of the first and second melanomas were not consistent. The proportion of subsequent melanomas that were in situ (51.5%) or thin melanomas (<1 mm, 24.2%) was higher compared with first melanomas (7.7%, respectively 11.5%). The median and mean time to diagnosis was 2.75 months, respectively, 28.09 months. In total, 76.92% of second melanomas were detected within three years, but we were able to document a subsequent melanoma more than ten years after the first diagnosis. The study highlights the importance of follow‑up in patients diagnosed with melanoma, not only in the first years after the primary diagnoses but for the entire life.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
2	Godar DE: Worldwide increasing incidence of cutaneous malignant melanoma. J Skin Cancer. 2011(858425)2011.
3	Tripp MK, Watson M, Balk SJ, Swetter SM and Gershenwald JE: State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 66:460–480. 2016.PubMed/NCBI View Article : Google Scholar
4	Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, et al: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 315:1600–1609. 2016.PubMed/NCBI View Article : Google Scholar
5	Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 386:444–451. 2015.PubMed/NCBI View Article : Google Scholar
6	Pastor-Tomás N, Martínez-Franco A, Bañuls J, Peñalver JC, Traves V, García-Casado Z, Requena C, Kumar R and Nagore E: Risk factors for the development of a second melanoma in patients with cutaneous melanoma. J Eur Acad Dermatol Venereol: Mar 12, 2020 (Online ahead of print).
7	Adler NR, Kelly JW, Haydon A, McLean CA and Mar VJ: Clinicopathological characteristics and prognosis of patients with multiple primary melanomas. Br J Dermatol. 178:e44–e45. 2018.PubMed/NCBI View Article : Google Scholar
8	Claeson M, Holmström P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM and Paoli J: Multiple primary melanomas: A common occurrence in Western Sweden. Acta Derm Venereol. 97:715–719. 2017.PubMed/NCBI View Article : Google Scholar
9	van der Leest RJT, Flohil SC, Arends LR, de Vries E and Nijsten T: Risk of subsequent cutaneous malignancy in patients with prior melanoma: A systematic review and meta-analysis. J Eur Acad Dermatology Venereol. 29:1053–1062. 2015.PubMed/NCBI View Article : Google Scholar
10	Caini S, Boniol M, Botteri E, Tosti G, Bazolli B, Russell-Edu W, Giusti F, Testori A and Gandini S: The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. J Dermatol Sci. 75:3–9. 2014.PubMed/NCBI View Article : Google Scholar
11	Bradford PT, Freedman DM, Goldstein AM and Tucker MA: Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 146:265–272. 2010.PubMed/NCBI View Article : Google Scholar
12	Spanogle JP, Clarke CA, Aroner S and Swetter SM: Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol. 62:757–767. 2010.PubMed/NCBI View Article : Google Scholar
13	Crocetti E, Guzzinati S, Paci E, Falcini F, Zanetti R, Vercelli M, Rashid I, De Lisi V, Russo A, Vitarelli S, et al: The risk of developing a second, different, cancer among 14560 survivors of malignant cutaneous melanoma: A study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res. 18:230–234. 2008.PubMed/NCBI View Article : Google Scholar
14	Bhatia S, Estrada-Batres L, Maryon T, Bogue M and Chu D: Second primary tumors in patients with cutaneous malignant melanoma. Cancer. 86:2014–2020. 1999.PubMed/NCBI View Article : Google Scholar
15	Espinosa P, Pfeiffer RM, García-Casado Z, Requena C, Landi MT, Kumar R and Nagore E: Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study. Eur J Cancer. 53:115–124. 2016.PubMed/NCBI View Article : Google Scholar
16	Moore MM, Geller AC, Warton EM, Schwalbe J and Asgari MM: Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol. 73:630–636. 2015.PubMed/NCBI View Article : Google Scholar
17	Slingluff CL Jr, Vollmer RT and Seigler HF: Multiple primary melanoma: Incidence and risk factors in 283 patients. Surgery. 113:330–339. 1993.PubMed/NCBI
18	Stam-Posthuma JJ, van Duinen C, Scheffer E, Vink J and Bergman W: Multiple primary melanomas. J Am Acad Dermatol. 44:22–27. 2011.
19	Titus-Ernstoff L, Perry AE, Spencer SK, Gibson J, Ding J, Cole B and Ernstoff MS: Multiple primary melanoma: Two-year results from a population-based study. Arch Dermatol. 142:433–438. 2006.PubMed/NCBI View Article : Google Scholar
20	Siskind V, Hughes MC, Palmer JM, Symmons JM, Aitken JF, Martin NG, Hayward NK and Whiteman DC: Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol. 131:461–467. 2011.PubMed/NCBI View Article : Google Scholar
21	Johnson TM, Hamilton T and Lowe L: Multiple primary melanomas. J Am Acad Dermatol. 39:422–427. 1998.PubMed/NCBI View Article : Google Scholar
22	Vecchiato A, Pasquali S, Menin C, Montesco MC, Alaibac M, Mocellin S, Campana LG, Nitti D and Rossi CR: Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. J Eur Acad Dermatol Venereol. 28:58–64. 2014.PubMed/NCBI View Article : Google Scholar
23	DiFronzo LA, Wanek LA and Morton DL: Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer. 91:1520–1524. 2001.PubMed/NCBI View Article : Google Scholar
24	De Giorgi V, Rossari S, Papi F, Gori A, Alfaioli B, Grazzini M, Crocetti E, Verdelli A, Foo CW and Lotti T: Multiple primary melanoma: The impact of atypical naevi and follow-up. Br J Dermatol. 163:1319–1322. 2010.PubMed/NCBI View Article : Google Scholar
25	Ilie MA, Caruntu C, Lupu M, Lixandru D, Tampa M, Georgescu SR, Bastian A, Constantin C, Neagu M, Zurac SA and Boda D: Current and future applications of confocal laser scanning microscopy imaging in skin oncology. Oncol Lett. 17:4102–4111. 2019.PubMed/NCBI View Article : Google Scholar
26	Ancuceanu R, Dinu M, Neaga I, Laszlo FG and Boda D: Development of QSAR machine learning-based models to forecast the effect of substances on malignant melanoma cells. Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar
27	Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endocrinol. 10:545–558. 2014.
28	Boda D: Cellomics as integrative omics for cancer. Curr Proteomics. 10:237–245. 2013.
29	Stefan O, Tudor G, Constantinescu C, Luca C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin and N-cadherin expression pattern in common melanocytic nevi. Virchows Archiv. 475 (Suppl)(S28)2019.
30	Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar
31	Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, et al: European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics-update 2019. Eur J Cancer. 126:141–158. 2020.PubMed/NCBI View Article : Google Scholar